Horak F, Jäger S, Berger U, Toth J, Nirnberger G, Kyrein H J, Rehn D, Vix J M
HNO-Universitätsklinik Währinger Gürtel, Wien, Austria.
Agents Actions. 1994 Jun;41 Spec No:C124-6. doi: 10.1007/BF02007795.
The aim of the study was to develop a laboratory system to challenge mite allergic patients with physiological concentrations of Der p I in order to evaluate the efficacy of antiallergic drugs in mite allergic patients. A double-blind, placebo-controlled, cross-over study was designed with three consecutive sessions. Twelve patients with proven sensitivity to dust mite were treated with a single dose of dimethindene maleate in a FOAD formulation (4 and 8 mg vs. placebo) 12 h before a long-term challenge with mite allergen Der p I in the Vienna challenge chamber. Challenge was performed with a constant concentration of 40 ng Der p I per cubic meter of air for 4 h. Nasal parameters were recorded at 15 min intervals during long-term challenge. In comparison to placebo, dimethindene leads to a statistically significant reduction (p < 0.05) of the nasal response at both concentrations tested. The house-dust mite model in the Vienna challenge chamber thus proved to be a useful tool for drug investigations in mite allergies.
该研究的目的是开发一种实验室系统，用生理浓度的Der p I对螨过敏患者进行激发试验，以评估抗过敏药物对螨过敏患者的疗效。设计了一项双盲、安慰剂对照、交叉研究，包括三个连续的阶段。12名经证实对尘螨敏感的患者，在维也纳激发试验舱内用螨过敏原Der p I进行长期激发试验前12小时，接受单剂量马来酸氯苯那敏FOAD制剂（4毫克和8毫克与安慰剂对照）治疗。以每立方米空气40纳克Der p I的恒定浓度进行4小时的激发试验。在长期激发试验期间，每隔15分钟记录一次鼻腔参数。与安慰剂相比，在两个测试浓度下，马来酸氯苯那敏均导致鼻腔反应在统计学上显著降低（p<0.05）。因此，维也纳激发试验舱内的屋尘螨模型被证明是用于螨过敏药物研究的有用工具。
